Natural Killer Cell Killing of Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia Blasts by Killer Cell Immunoglobulin-Like Receptor-Negative Natural Killer Cells after NKG2A and LIR-1 Blockade

Biology of Blood and Marrow Transplantation

Volumn 16, Issue 5, 2010, Pages 612-621

  Godal, Robert ^a   Bachanova, Veronika ^a   Gleason, Michelle ^a   McCullar, Valarie ^a   Yun, Gong H ^a   Cooley, Sarah ^a   Verneris, Michael R ^a   McGlave, Philip B ^a   Miller, Jeffrey S ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Immunotherapy; Leukemia; NK cells

Indexed keywords

HLA ANTIBODY; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; LEUKOCYTE IMMUNOGLOBULIN RECEPTOR 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NATURAL KILLER CELL RECEPTOR NKG2A; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOIMMUNITY; ARTICLE; BLAST CELL; CANCER IMMUNOTHERAPY; CELL KILLING; CELL POPULATION; CLINICAL ARTICLE; CYTOLYSIS; CYTOTOXICITY; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IMMUNOLOGICAL TOLERANCE; NATURAL KILLER CELL; PROTEIN FUNCTION; PROTEIN INTERACTION; RECEPTOR BLOCKING; SIGNAL TRANSDUCTION;

ANTIBODIES; ANTIGENS, CD; BLAST CRISIS; CELLS, CULTURED; CYTOTOXICITY, IMMUNOLOGIC; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; KILLER CELLS, NATURAL; LEUKEMIA, MYELOID, ACUTE; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY C; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECEPTORS, IMMUNOLOGIC; RECEPTORS, KIR;

EID: 77951174364     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2010.01.019     Document Type: Article

References (46)

1. Lopez-Botet M., Llano M., Navarro F., et al. NK cell recognition of non-classical HLA class I molecules. Semin Immunol 2000, 12:109-119.
2. Parham P. MHC class I molecules and KIRs in human history, health and survival. Nat Rev Immunol 2005, 5:201-214.
3. Caligiuri M.A. Human natural killer cells. Blood 2008, 112:461-469.
4. Lanier L.L. Evolutionary struggles between NK cells and viruses. Nat Rev Immunol 2008, 8:259-268.
5. Kim S., Poursine-Laurent J., Truscott S.M., et al. Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature 2005, 436:709-713.
6. Raulet D.H., Vance R.E. Self-tolerance of natural killer cells. Nat Rev Immunol 2006, 6:520-531.
7. Anfossi N., Andre P., Guia S., et al. Human NK cell education by inhibitory receptors for MHC class I. Immunity 2006, 25:331-342.
8. Lee N., Llano M., Carretero M., et al. HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A. Proc Natl Acad Sci USA 1998, 95:5199-5204.
9. Cosman D., Fanger N., Borges L., et al. A novel immunoglobulin superfamily receptor for cellular and viral MHC class I molecules. Immunity 1997, 7:273-282.
10. Colonna M., Navarro F., Bellon T., et al. A common inhibitory receptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells. J Exp Med 1997, 186:1809-1818.
11. Riteau B., Menier C., Khalil-Daher I., et al. HLA-G1 co-expression boosts the HLA class I-mediated NK lysis inhibition. Int Immunol 2001, 13:193-201.
12. Riteau B., Rouas-Freiss N., Menier C., et al. HLA-G2, -G3, and -G4 isoforms expressed as nonmature cell surface glycoproteins inhibit NK and antigen-specific CTL cytolysis. J Immunol 2001, 166:5018-5026.
13. Shilling H.G., McQueen K.L., Cheng N.W., et al. Reconstitution of NK cell receptor repertoire following HLA-matched hematopoietic cell transplantation. Blood 2003, 101:3730-3740.
14. Vitale C., Chiossone L., Morreale G., et al. Analysis of the activating receptors and cytolytic function of human natural killer cells undergoing in vivo differentiation after allogeneic bone marrow transplantation. Eur J Immunol 2004, 34:455-460.
15. Cooley S., McCullar V., Wangen R., et al. KIR reconstitution is altered by T cells in the graft and correlates with clinical outcomes after unrelated donor transplantation. Blood 2005, 106:4370-4376.
16. Ruggeri L., Capanni M., Urbani E., et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002, 295:2097-2100.
17. Miller J.S., Cooley S., Parham P., et al. Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT. Blood 2007, 109:5058-5061.
18. Leung W., Iyengar R., Turner V., et al. Determinants of antileukemia effects of allogeneic NK cells. J Immunol 2004, 172:644-650.
19. Hsu K.C., Keever-Taylor C.A., Wilton A., et al. Improved outcome in HLA-identical sibling hematopoietic stem cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood 2005, 105:4878-4884.
20. Giebel S., Locatelli F., Lamparelli T., et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood 2003, 102:814-819.
21. Nguyen S., Dhedin N., Vernant J.P., et al. NK cell reconstitution after haploidentical hematopoietic stem cell transplantations: immaturity of NK cells and inhibitory effect of NKG2A override GvL effect. Blood 2005, 105:4135-4142.
22. Vago L., Forno B., Sormani M.P., et al. Temporal, quantitative, and functional characteristics of single-KIR-positive alloreactive natural killer cell recovery account for impaired graft-versus-leukemia activity after haploidentical hematopoietic stem cell transplantation. Blood 2008, 112:3488-3499.
23. Farag S.S., Bacigalupo A., Eapen M., et al. The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the Center for International Blood and Marrow Transplant Research, the European Blood and Marrow Transplant Registry, and the Dutch Registry. Biol Blood Marrow Transplant 2006, 12:876-884.
24. Malmberg K.J., Schaffer M., Ringden O., et al. KIR-ligand mismatch in allogeneic hematopoietic stem cell transplantation. Mol Immunol 2005, 42:531-534.
25. Yun G., Tolar J., Yerich A.K., et al. A novel method for KIR-ligand typing by pyrosequencing to predict NK cell alloreactivity. Clin Immunol 2007, 123:272-280.
26. Paul P., Rouas-Freiss N., Moreau P., et al. HLA-G, -E, -F preworkshop: tools and protocols for analysis of non-classical class I gene transcription and protein expression. Hum Immunol 2000, 61:1177-1195.
27. Menier C., Saez B., Horejsi V., et al. Characterization of monoclonal antibodies recognizing HLA-G or HLA-E: new tools to analyze the expression of nonclassical HLA class I molecules. Hum Immunol 2003, 64:315-326.
28. McCullar V., Oostendorp R., Panoskaltsis-Mortari A., et al. Mouse fetal and embryonic liver cells differentiate human umbilical cord blood progenitors into CD56-negative natural killer cell precursors in the absence of interleukin-15. Exp Hematol 2008, 36:598-608.
29. Piriou L., Chilmonczyk S., Genetet N., et al. Design of a flow cytometric assay for the determination of natural killer and cytotoxic T-lymphocyte activity in human and in different animal species. Cytometry 2000, 41:289-297.
30. Pozarowski P., Grabarek J., Darzynkiewicz Z. Flow cytometry of apoptosis. Curr Protoc Cell Biol 2004, Chap 18:Unit 18 18. 10.1002/0471143030.cb1808s21.
31. Godal R., Keilholz U., Uharek L., et al. Lymphomas are sensitive to perforin-dependent cytotoxic pathways despite expression of PI-9 and overexpression of bcl-2. Blood 2006, 107:3205-3211.
32. + T cells by a flow cytometric assay for degranulation. J Immunol Methods 2003, 281:65-78.
33. Rubio V., Stuge T.B., Singh N., et al. Ex vivo identification, isolation and analysis of tumor-cytolytic T cells. Nat Med 2003, 9:1377-1382.
34. Perez-Villar J.J., Melero I., Navarro F., et al. The CD94/NKG2-A inhibitory receptor complex is involved in natural killer cell-mediated recognition of cells expressing HLA-G1. J Immunol 1997, 158:5736-5743.
35. Navarro F., Llano M., Bellon T., et al. The ILT2(LIR1) and CD94/NKG2A NK cell receptors respectively recognize HLA-G1 and HLA-E molecules co-expressed on target cells. Eur J Immunol 1999, 29:277-283.
36. Pende D., Spaggiari G.M., Marcenaro S., et al. Analysis of the receptor-ligand interactions in the natural killer-mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the poliovirus receptor (CD155) and nectin-2 (CD112). Blood 2005, 105:2066-2073.
37. Polakova K., Krcova M., Kuba D., et al. Analysis of HLA-G expression in malignant hematopoetic cells from leukemia patients. Leuk Res 2003, 27:643-648.
38. Yan W.H., Lin A., Chen B.G., et al. Unfavourable clinical implications for HLA-G expression in acute myeloid leukaemia. J Cell Mol Med 2008, 12:889-898.
39. Apps R., Gardner L., Moffett A. A critical look at HLA-G. Trends Immunol 2008, 29:313-321.
40. Moreau P., Adrian-Cabestre F., Menier C., et al. IL-10 selectively induces HLA-G expression in human trophoblasts and monocytes. Int Immunol 1999, 11:803-811.
41. Romagne F., Andre P., Spee P., et al. Pre-clinical characterization of 1-7F9, a novel human anti-KIR therapeutic antibody that augments NK-mediated killing of tumor cells. Blood 2009, 114:2667-2677.
42. + NK cell clones. Int Immunol 1999, 11:29-35.
43. Freud A.G., Becknell B., Roychowdhury S., et al. A human CD34(+) subset resides in lymph nodes and differentiates into CD56bright natural killer cells. Immunity 2005, 22:295-304.
44. Freud A.G., Yokohama A., Becknell B., et al. Evidence for discrete stages of human natural killer cell differentiation in vivo. J Exp Med 2006, 203:1033-1043.
45. Yawata M., Yawata N., Draghi M., et al. MHC class I-specific inhibitory receptors and their ligands structure diverse human NK-cell repertoires toward a balance of missing self-response. Blood 2008, 112:2369-2380.
46. Yu J., Venstrom J.M., Liu X.R., et al. Breaking tolerance to self, circulating natural killer cells expressing inhibitory KIR for non-self HLA exhibit effector function after T cell-depleted allogeneic hematopoietic cell transplantation. Blood 2009, 113:3875-3884.